Enovis
ENOV · Health Care Equipment
$21.08
2.4%Revvity
RVTY · Health Care Equipment
$158.77
0.9%The short version
- Revvity is the larger business, with $2.9B of revenue in fiscal 2025 against $2.2B for Enovis.
- Enovis grew revenue faster (6.7%, against 3.7%).
- Revvity kept more of each dollar of sales as operating profit (12.5% operating margin, against −50.0% operating margin).
- Revvity turned more of its sales into free cash flow (17.8% FCF margin, against 0.9% FCF margin).
- Revvity earned a higher return on the capital invested in it (3.3%, against −26.9%).
| Latest fiscal year | ENOV · FY25 | RVTY · FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.2B | $17.7B |
| Revenue | $2.2B | $2.9B |
| Free cash flow | $19.9M | $509M |
| Net income | −$1.2B | $241M |
| Growth | ||
| Revenue growth | 6.7% | 3.7% |
| 5-year growth | 14.9% | −5.5% |
| Share count change | 3.2% | −5.1% |
| Profitability | ||
| Gross margin | 59.8% | — |
| Operating margin | −50.0% | 12.5% |
| Net margin | −52.7% | 8.5% |
| FCF margin | 0.9% | 17.8% |
| Return on capital | −26.9% | 3.3% |
| Return on equity | −58.5% | 3.2% |
| Balance sheet | ||
| Net debt | $1.3B | $2.3B |
| Net debt / EBITDA | 5.7x | 3.0x |
| Dividends and buybacks | $3.5M | $854M |
| Valuation & quality | ||
| P/E | — | 76.0x |
| Piotroski F-score | 4 | 5 |
FY16
ENOV $3.2B
RVTY $2.1B
FY17
ENOV $1.9B
RVTY $2.3B
FY18
ENOV $2.2B
RVTY $2.8B
FY19
ENOV $3.3B
RVTY $2.9B
FY20
ENOV $1.1B
RVTY $3.8B
FY21
ENOV $1.4B
RVTY $3.8B
FY22
ENOV $1.6B
RVTY $3.3B
FY23
ENOV $1.7B
RVTY $2.8B
FY24
ENOV $2.1B
RVTY $2.8B
FY25
ENOV $2.2B
RVTY $2.9B
ENOV
RVTY
FY16
ENOV 7.4%
RVTY 13.9%
FY17
ENOV 7.0%
RVTY 13.1%
FY18
ENOV 6.9%
RVTY 11.7%
FY19
ENOV 6.1%
RVTY 12.6%
FY20
ENOV −5.9%
RVTY 22.9%
FY21
ENOV −4.4%
RVTY 32.9%
FY22
ENOV −4.6%
RVTY 22.4%
FY23
ENOV −3.9%
RVTY 10.9%
FY24
ENOV −36.8%
RVTY 12.6%
FY25
ENOV −50.0%
RVTY 12.5%
ENOV
RVTY
FY16
ENOV $184M
RVTY $319M
FY17
ENOV $150M
RVTY $249M
FY18
ENOV $157M
RVTY $218M
FY19
ENOV $5.6M
RVTY $287M
FY20
ENOV $187M
RVTY $829M
FY21
ENOV $252M
RVTY $1.3B
FY22
ENOV −$161M
RVTY $594M
FY23
ENOV $12.8M
RVTY $9.9M
FY24
ENOV −$67.2M
RVTY $542M
FY25
ENOV $19.9M
RVTY $509M
ENOV
RVTY
FY16
ENOV 4.1%
RVTY 9.1%
FY17
ENOV 3.0%
RVTY 4.4%
FY18
ENOV 3.4%
RVTY 6.9%
FY19
ENOV 2.0%
RVTY 7.7%
FY20
ENOV −0.9%
RVTY 13.6%
FY21
ENOV −0.8%
RVTY 11.0%
FY22
ENOV −1.2%
RVTY 5.1%
FY23
ENOV −1.4%
RVTY 2.7%
FY24
ENOV −15.9%
RVTY 3.1%
FY25
ENOV −26.9%
RVTY 3.3%
ENOV
RVTY
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.